- In late June 2026, Haemonetics Corporation (NYSE: HAE) was added to multiple Russell value-oriented and defensive benchmarks, including the Russell 2000 Value, Russell 2500 Value, Russell Small Cap Comp Value, Russell 3000 Value, and Russell 3000E Value indexes.
- This broad inclusion across several Russell value and defensive indexes can increase passive ownership, deepen liquidity, and reinforce Haemonetics’ positioning as a value-tilted medtech name in institutional portfolios.
- We’ll now examine how Haemonetics’ broad inclusion in multiple Russell value indexes may influence its existing investment narrative and risk profile.
Rare earth metals are the new gold rush. Find out which 30 stocks are leading the charge.
Haemonetics Investment Narrative Recap
To own Haemonetics, you need to believe in its ability to grow earnings from a focused medtech portfolio while managing U.S. concentration, product dependence, and elevated debt. The broad addition to Russell value and defensive indexes primarily affects trading dynamics and investor mix rather than the near term business story, so it does not materially change the key catalyst around execution in core franchises or the central risk tied to concentrated revenue streams and margin pressure.
The recent FDA labeling expansion for VASCADE MVP XL is especially relevant here, as it directly targets one of Haemonetics’ key growth areas in vascular closure. While the Russell index inclusions may support liquidity and passive ownership, many investors will likely keep their attention on how quickly this expanded indication translates into better utilization and whether it helps offset recent earnings pressure and the one off loss that weighed on FY2026 results.
Yet beneath the index additions, investors should also be aware of the risk that…
Read the full narrative on Haemonetics (it’s free!)
Haemonetics’ narrative projects $1.5 billion revenue and $247.6 million earnings by 2029.
Uncover how Haemonetics’ forecasts yield a $86.90 fair value, a 12% upside to its current price.
Exploring Other Perspectives
By contrast, the most bearish analysts were modeling revenue of about US$1.5 billion and earnings of roughly US$252.5 million by 2029, reminding you that views on execution risk and demand for vascular closure can diverge sharply and that both bullish and cautious narratives may need to be reassessed in light of Haemonetics’ new status in multiple Russell value indexes.
Explore 2 other fair value estimates on Haemonetics – why the stock might be worth as much as 64% more than the current price!
Form Your Own Verdict
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
Searching For A Fresh Perspective?
The market won’t wait. These fast-moving stocks are hot now. Grab the list before they run:
This article by Simply Wall St is general in nature. We provide commentary based on historical data
…
Read More: Haemonetics’ Broad Russell Value Index Inclusion Might Change The Case For
